GlassScriptPhysician profile
Steven E Burdine
NPI 1356563969
$4,415.41
in general payments reported to CMS, 2019-2025
48 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $454 · 2021: $871 · 2022: $776 · 2023: $882 · 2024: $517 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.93 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $535.96 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.80 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $298.30 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $295.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $278.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.58 | 2019-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Novo Nordisk INC | $225.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $171.28 | 2019-2023 | |
| Abbvie INC. | $169.30 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $159.99 | 2019-2024 | Gardasil 9, Vaxneuvance, Verquvo |
| Exact Sciences Corporation | $128.09 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.14 | 2020-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $115.93 | 2019-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $113.44 | 2019-2025 | Veozah |
| Insulet Corporation | $100.71 | 2021-2023 | Omnipod |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Burdine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.